Ignite Creation Date:
2025-12-24 @ 5:56 PM
Ignite Modification Date:
2025-12-25 @ 3:20 PM
Study NCT ID:
NCT04003168
Status:
UNKNOWN
Last Update Posted:
2021-03-01
First Post:
2019-06-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D009101', 'term': 'Multiple Myeloma'}, {'id': 'D012008', 'term': 'Recurrence'}], 'ancestors': [{'id': 'D054219', 'term': 'Neoplasms, Plasma Cell'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D020141', 'term': 'Hemostatic Disorders'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D010265', 'term': 'Paraproteinemias'}, {'id': 'D001796', 'term': 'Blood Protein Disorders'}, {'id': 'D006402', 'term': 'Hematologic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D006474', 'term': 'Hemorrhagic Disorders'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 18}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2019-07-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-02', 'completionDateStruct': {'date': '2024-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2021-02-25', 'studyFirstSubmitDate': '2019-06-24', 'studyFirstSubmitQcDate': '2019-06-28', 'lastUpdatePostDateStruct': {'date': '2021-03-01', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-07-01', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-07', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of participants with treatment-related adverse events as assessed by NCI-CTCAE 5.0', 'timeFrame': '28 days post infusion'}], 'secondaryOutcomes': [{'measure': 'Concentration of Anti-BCMA CAR T Cells in blood', 'timeFrame': '2 years post infusion'}, {'measure': 'Concentration of Anti-BCMA CAR T Cells in bone marrow', 'timeFrame': '2 years post infusion'}, {'measure': 'Pharmacodynamics (Levels of Cytokines in Serum)', 'timeFrame': '2 years post infusion'}, {'measure': 'Pharmacodynamics (Content of clonal plasma cells in bone marrow)', 'timeFrame': '2 years post infusion'}, {'measure': 'Overall response rate (ORR) after administration', 'timeFrame': '3 months post infusion'}, {'measure': 'Negative proportion of minimal residual disease (MRD)', 'timeFrame': '28 days post infusion'}, {'measure': 'Duration of remission (DOR) after administration', 'timeFrame': '2 years post infusion'}, {'measure': 'Progress Free Survival (PFS) after administration', 'timeFrame': '2 years post infusion'}, {'measure': 'Overall Survival (OS)after administration', 'timeFrame': '2 years post infusion'}, {'measure': 'Positive incidence of anti-drug antibody', 'timeFrame': '2 years post infusion'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['BCMA', 'CAR-T', 'multiple myeloma', 'Relapsed/Refractory'], 'conditions': ['Multiple Myeloma']}, 'referencesModule': {'references': [{'pmid': '36536403', 'type': 'DERIVED', 'citation': 'Wang H, Tsao ST, Gu M, Fu C, He F, Li X, Zhang M, Li N, Hu HM. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count. J Transl Med. 2022 Dec 19;20(1):608. doi: 10.1186/s12967-022-03833-6.'}]}, 'descriptionModule': {'briefSummary': 'To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of BCMA CAR+ T cells.', 'detailedDescription': 'Participants with BCMA-positive relapsed/refractory multiple myeloma can participate if all eligibility criteria are met. Tests required to determine eligibility include disease assessments, a physical exam, Electrocardiograph, CT/MRI/PET, and blood draws. Participants receive chemotherapy prior to the infusion of BCMA CAR+ T cells. After the infusion, participants will be followed for side effects and effect of BCMA CAR+ T cells. Study procedures may be performed while hospitalized.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Subjects volunteer to participate in clinical research, understand and know the research and sign informed consent document, willing to complete all the trial procedures;\n2. 18 to 70 Years Old, Male and female;\n3. Expected survival \\> 12 weeks;\n4. Previously diagnosed as multiple myeloma by IMWG updated criteria (2014);\n5. Patients with positive pathological test results or flow cytometry proving that BCMA expression of malignant plasma cells in bone marrow or plasma cell tumors ≥30%;\n6. One of the following indicators is satisfied:\n\n 1. Serum M protein IgG ≥ 10 g/L, or IgA \\> 10 mg/L, or IgD \\> 5 mg/L;\n 2. Urine M protein ≥ 200 mg/24h;\n 3. Serum free light chain ≥ 100 mg/L;\n7. Patients with relapsed/refractory multiple myeloma. Relapsed is defined as:\n\n Patients have disease progression after at least three-line treatment regimens. Patients previously received at least 3 different mechanisms treatment regimens for multiple myeloma, including protease inhibitors and immunomodulators, and have disease progression within 60 days of the latest treatment ; Refractory is defined as: Patients who achieved remission in the piror therapies, have disease progression within 60 days, or after the latest therapy.\n8. Those who relapse 90 days after stem cell transplantation\n9. ECOG score 0-1;\n10. Liver, kidney and cardiopulmonary functions meet the following requirements:\n\n 1. Creatinine clearance (estimated by Cockcroft Gault formula) ≥ 40 mL/min;\n 2. Left ventricular ejection fraction \\>50%;\n 3. Baseline peripheral oxygen saturation \\>95%;\n 4. Total bilirubin ≤ 2×ULN; ALT and AST ≤2.5 × ULN;\n11. The venous access required for collection can be established, and no leukocyte collection contraindications.\n\nExclusion Criteria:\n\n1. Accompanied by other uncontrolled malignancies;\n2. Subjects with positive HBsAg or HBcAb and peripheral blood HBV DNA titer is higher than the lower limit of detection of the research institution; HCV antibody positive and peripheral blood HCV RNA positive; HIV antibody positive; syphilis primary screening antibody positive;\n3. Any instability of systemic disease, including but not limited to unstable angina, cerebrovascular accident, or transient cerebral ischemic (within 6 months prior to screening), myocardial infarction (within 6 months prior to screening), congestive heart failure (New York heart association (NYHA) classification ≥ III), severe arrhythmia, liver, kidney or metabolic disease with poor drug control;\n4. Patients who are accounted to be not appropriate for this trail by investigator;\n5. Pregnant or lactating, or planning to have a pregnancy during or within 1 year after treatment;\n6. Received CAR-T treatment or other gene therapies before enrollment;\n7. Those who failed to sign informed consent form or comply with the research procedures; Unwilling or unable to comply with research requirements;\n8. Have had severe immediate hypersensitivity reactions to any drugs used in this research;\n9. The presence or suspicion of fungi, bacteria, viruses or other infections that are uncontrollable or requiring intravenous treatment;\n10. In the past two years, the terminal organ was damaged due to autoimmune diseases (such as crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), or the systemic use of immunosuppressive or other systemic disease control drugs was required;\n11. Have a history of central nervous system (CNS) disease, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain damage, dementia, Parkinson's disease, psychosis."}, 'identificationModule': {'nctId': 'NCT04003168', 'briefTitle': 'Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hrain Biotechnology Co., Ltd.'}, 'officialTitle': 'A Phase I Clinical Trial to Evaluate the Safety and Efficacy of Human BCMA Targeted T Cells Injection for Subjects With BCMA-positive Relapsed/Refractory Multiple Myeloma', 'orgStudyIdInfo': {'id': 'HRAIN01-MM01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Human BCMA targeted T Cells Injection', 'description': 'A single infusion of anti-BCMA CAR transduced T cells administered intravenously at a target dose of 3 to 9 x 10\\^6 CAR T +cells/kg. The classic "3+3" dose escalation will be applied.', 'interventionNames': ['Drug: Human BCMA targeted T Cells Injection']}], 'interventions': [{'name': 'Human BCMA targeted T Cells Injection', 'type': 'DRUG', 'description': 'Autologous genetically modified anti-BCMA CAR transduced T cells', 'armGroupLabels': ['Human BCMA targeted T Cells Injection']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Zhengzhou', 'state': 'Henan', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Zhi Cheng, M.D.', 'role': 'CONTACT', 'email': 'clinicaltrials.chengzhi@outlook.com', 'phone': '+(86)-139-3852-6995'}], 'facility': 'The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine', 'geoPoint': {'lat': 34.75778, 'lon': 113.64861}}, {'zip': '200003', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Weijun Fu, Professor', 'role': 'CONTACT', 'email': 'fuweijun2010@hotmail.com', 'phone': '021-81885423'}], 'facility': 'Shanghai Changzheng Hospital', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '325000', 'city': 'Wenzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Kang Yu, Professor', 'role': 'CONTACT', 'email': 'yukang62@126.com', 'phone': '0577-55579486'}], 'facility': 'The First Affiliated Hospital of Wenzhou Medical University', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}], 'centralContacts': [{'name': 'Hongliang Fang, doctor', 'role': 'CONTACT', 'email': 'fanghongliang@dashengbio.com', 'phone': '021-58552006'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hrain Biotechnology Co., Ltd.', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Shanghai Changzheng Hospital', 'class': 'OTHER'}, {'name': 'First Affiliated Hospital of Wenzhou Medical University', 'class': 'OTHER'}, {'name': 'The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}